Delta-like ligand 3 and CD3

The phrase "Delta-like ligand 3 and CD3" refers to a therapeutic strategy, primarily exploited by bispecific antibodies like tarlatamab, which simultaneously target delta-like ligand 3 (DLL3) on tumor cells and CD3 on T cells. This co-targeting is designed to bring T cells into close proximity with tumor cells, initiating T cell activation and subsequent tumor cell killing. It is not a single, naturally occurring molecular entity or complex, but rather describes the artificial pairing of two distinct proteins for therapeutic purposes. If a structured database requires a canonical target entry, 'Delta-like ligand 3' and 'T cell surface glycoprotein CD3 complex' should be cataloged independently with cross-references for bispecific or multi-specific therapeutic modalities.

The phrase refers to a drug development strategy involving the co-targeting of DLL3 on tumor cells and CD3 on T cells. Bispecific antibodies (e.g., tarlatamab) bind DLL3 on tumor cells and CD3 on T cells, redirecting T-cell cytotoxicity to DLL3-expressing tumor cells, leading to tumor cell lysis independent of traditional antigen presentation. This strategy harnesses immune cell cytotoxicity for selective cancer killing.